SK biopharmaceuticals Co., Ltd.
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
326030 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 분당구 판교역로 221, 성남시
- Website:
- https://www.skbp.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
SK Biopharmaceuticals is a global, fully integrated pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies. The company's primary therapeutic area is central nervous system (CNS) disorders, with an expanding pipeline in oncology. Its business model encompasses the entire value chain, from research and development to direct commercialization in key global markets, particularly the United States. The company's flagship product is cenobamate (marketed as XCOPRI® in the U.S.), an anti-seizure medication that has demonstrated significant commercial growth. SK Biopharmaceuticals actively incorporates advanced technologies, including artificial intelligence, to accelerate its drug development process and address unmet medical needs.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SK biopharmaceuticals Co., Ltd. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all SK biopharmaceuticals Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for SK biopharmaceuticals Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
